Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study-Reference-Cited by-同舟云学术

Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study

Published:2022-07 Issue: Volume:160 Page:116416
ISSN:8756-3282
Container-title:Bone
language:en
Short-container-title:Bone

Author:

Chiba Ko,Okazaki Narihiro,Kurogi Ayako,Watanabe Tsuyoshi,Mori Ai,Suzuki Nobuhiko,Adachi Koichi,Era Makoto,Yokota Kazuaki,Inoue Takuma,Yabe Yoshihiro,Furukawa Keizo,Kondo Choko,Tsuda Keiichi,Ota Shingo,Isobe Yusaku,Miyazaki Satsuki,Morimoto Shimpei,Sato Shuntaro,Nakashima Sawako,Tashiro Shigeki,Yonekura Akihiko,Tomita Masato,Osaki Makoto

Funder

Asahi Kasei Pharma Corporation

Eli Lilly Japan

Publisher

Elsevier BV

Subject

Histology,Physiology,Endocrinology, Diabetes and Metabolism

Reference27 articles.

1. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis;Neer;N. Engl. J. Med.,2001

2. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases;Miyauchi;Bone,2010

3. Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk;Nakamura;J. Clin. Endocrinol. Metab.,2012

4. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan fracture observational study (JFOS);Soen;Curr. Med. Res. Opin.,2017

5. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis;Cummings;J. Bone Miner. Res.,2017

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study;Bone;2024-10

2. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

3. Can Bisphosphonate Therapy Reduce Overall Mortality in Patients With Osteoporosis? A Meta-analysis of Randomized Controlled Trials;Clinical Orthopaedics & Related Research;2024-08-22

4. Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-08-07

5. Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS);Expert Opinion on Drug Safety;2024-07-18